<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014884</article-id><article-id pub-id-type="pmcid-ver">PMC2014884.1</article-id><article-id pub-id-type="pmcaid">2014884</article-id><article-id pub-id-type="pmcaiid">2014884</article-id><article-id pub-id-type="pmid">10606836</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00113.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jorga</surname><given-names initials="K">Karin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fotteler</surname><given-names initials="B">B&#228;rbel</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Banken</surname><given-names initials="L">Ludger</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snell</surname><given-names initials="P">Paul</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Steimer</surname><given-names initials="JL">Jean-Louis</given-names></name></contrib><aff><institution>Department of Research and Development, F. Hoffmann-La Roche Ltd</institution><addr-line>Basel, Switzerland</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Dr Karin Jorga, Department of Clinical Pharmacology, F. Hoffmann-La Roche, CH-4070 Basel, Switzerland, Tel.: +41 61 688 1449 (Work), Tel.: +49 76 3174 9687 (Home), Fax: +41 61 688 1043, E-mail: <email>karin.jorga@roche.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2000</year></pub-date><volume>49</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">151575</issue-id><fpage>39</fpage><lpage>48</lpage><history><date date-type="received"><day>12</day><month>5</month><year>1999</year></date><date date-type="accepted"><day>27</day><month>9</month><year>1999</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:37:05.187"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0049-0039.pdf"/><abstract><sec><title>Aims</title><p>To use pharmacostatistical models to characterize tolcapone's pharmacokinetics in parkinsonian patients, and to identify any demographic subpopulations which may be at risk of either under- or over-exposure to this catechol-<italic>O</italic>-methyltransferase (COMT) inhibitor.</p></sec><sec sec-type="methods"><title>Methods</title><p>Four hundred and twelve patients participated in three multicentre, parallel, double-blind, placebo-controlled, dose-finding studies and received either placebo or tolcapone (50, 200 or 400 mg three times daily) in addition to levodopa/decarboxylase inhibitor therapy. Sparse blood samples were obtained from 275 patients for tolcapone assay and the concentrations (1414 in total) were analysed using the NONMEM program.</p></sec><sec><title>Results</title><p>The pharmacokinetic model which best described the data was a two-compartment open model with first-order absorption and possibly a lag-time. Tolcapone pharmacokinetics were shown to be stable, with no systematic trend between 2 and 6 weeks of treatment. The absorption of the drug was shown to be rapid and concomitant food intake had only a minor effect on the relative bioavailability (10&#8211;20% reduction compared with fasting). The overall clearance of tolcapone could be estimated with good precision (approximately 4.5&#8211;5 l h<sup>&#8722;1</sup>), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter. The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5&#8211;8 h.</p></sec><sec><title>Conclusions</title><p>Using sparse concentrations and mixed effect-effects modelling analysis it is possible to describe the pharmacokinetics of tolcapone in parkinsonian populations. The parameter estimates obtained agreed with those obtained from conventional pharmacokinetic studies and no subpopulation was shown to be at risk of either under- or over-exposure to tolcapone.</p></sec></abstract><kwd-group><kwd>COMT inhibitor</kwd><kwd>pharmacokinetics</kwd><kwd>tolcapone</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>